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To the Editor: In their commentary on the Hemmelgarn
et al.1 study of kidney dysfunction in the elderly, Locatelli and
Pozzoni2 note that patients with the most progressive disease
were the most likely to have been treated with renin–angio-
tensin system inhibitors (RASIs). They suggest that ‘ythis
association can be explained by selection bias’. An alternative
explanation may be that the RASIs (and the increased use
of diuretics in this group) led to hemodynamic-mediated
declines in glomerular filtration rate.
It is well known that RASIs lead to immediate declines in
glomerular filtration rate based largely on reduction of intra-
glomerular pressure.3 These declines are tolerated because the
reduction in intraglomerular pressure is believed to con-
tribute toward long-term deceleration of kidney disease
progression,3 and because the hemodynamic changes are
reversible; for example, Bakris and Weir3 substituted
clonidine for angiotensin-converting enzyme inhibitors in
patients with chronic kidney disease (CKD) and documented
a mean increase in glomerular filtration rate ofB10 ml/min.
The improvement in glomerular filtration rate that follows
discontinuation of RASIs, and the long-term beneficial effect
of (nevertheless) continuing RASIs, are both well known.
However, nephrologists have not yet synthesized a unified
strategy for treating CKD that applies all of this information
in a complementary manner. That strategy might be
applicable in late stage 4 CKD, as initiation of dialysis
appears imminent. In other words, a comprehensive strategy
might emphasize aggressive RAS inhibition to stabilize CKD
throughout most of its course, but would also recognize that
for patients who eventually do progress to end-stage renal
disease, RASIs will have outlived their usefulness in
preventing end-stage renal disease. At that very late stage,
instead of starting dialysis, discontinuation of RASIs may
lead to increases in glomerular filtration rate of B3–10 ml/
min,3,4 which, in some patients, may delay dialysis initiation
for several additional years.
Treatment of CKD with RASIs has been studied (and
exhorted) throughout the course of CKD up to early stage 4.5
We have not formally studied the use of RASIs at late stage 4.
Such a study appears warranted to evaluate the approach
described. It will need to address appropriate patient
selection, with sensitivity towards patients who require RASIs
for heart disease. It will also need to address other nuances
including timing, substitute medicines and levels of blood
pressure control, and measure not only dialysis-free intervals
but also overall outcomes.
In the absence of data in late stage 4 CKD, physicians
should remain aware of the reversible hemodynamic effects
of RASI inhibitors and diuretics, and may consider a short
trial of manipulation of these medicines, in selected patients,
in lieu of immediate initiation of dialysis.
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We are grateful to Dr Hirsch1 for his comment.
We are of course aware that the use of renin–angiotensin
system inhibitors (RASIs) may cause hemodynamic-media-
ted declines in glomerular filtration rate. This was clearly
seen in the Angiotensin-Converting Enzyme Inhibition in
Progressive Renal Insufficiency (AIPRI) study:2 the
patients in the benazepril arm experienced significantly
higher serum creatinine levels than those randomized to
placebo during the first 6 months of treatment, although
their renal survival during follow-up was statistically much
better. It is for this reason that the use of these drugs
should be carefully weighed, particularly in elderly
patients with diffuse atherosclerotic lesions, and above
all if they are being administered diuretics. It should also
be borne in mind that, as was documented in the study by
Himmelgarn et al.,3 such patients frequently make use of
non-steroidal anti-inflammatory drugs (often without even
informing their physician) and this may further contribute
to renal impairment.
We consequently also agree that, in the case of a major
deterioration in renal function, an attempt to discontinue
RASIs should be encouraged before deciding to start
dialysis in the later stages of chronic kidney disease.
However, the hypothetical deterioration in renal function
in the patients taking part in the study by Himmelgarn
et al.3 with the most advanced degree of renal impairment
was too great to be attributable to the effect of RASIs; we
also have no information about the duration of RASI
treatment or the deterioration in renal function during the
treatment itself.
The main message we wanted to send through our
commentary was that we cannot expect the positive
renoprotective effects of RASIs seen in younger patients
with overt proteinuria (mainly secondary to glomerulo-
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nephritis or diabetic nephropathy) participating in con-
trolled, randomized clinical trials to be automatically
transferred to everyday clinical practice. The general
population is getting increasingly older every year, and
the majority of treated patients are elderly subjects with
nephroangiosclerosis and little or no proteinuria, with no
actual possibility for checking for renal artery stenosis. We
should remember, for example, what the RALES study
taught us about the risk of hyperkalemia when its results
were translated into everyday clinical practice.4
Another aspect we wanted to underline was that we
should not only look at deteriorating renal function but
also (and above all) cardiovascular prevention, because
many more chronic kidney disease patients in the general
population die before needing dialysis than actually start
chronic dialysis even in the most advanced stages of the
disease.5,6 This is a rather different scenario from what is
observed in randomized, controlled clinical trials, and
further underlines the need for randomized clinical studies
of older patients with more comorbidities and a greater
likelihood of vascular disease as the cause of their chronic
kidney disease. Such studies should consider cardiovascu-
lar as well as renal end points in order to evaluate the cost-
effectiveness of RASI administration in such a non-selected
patient population.
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To the Editor: In their interesting study, Kakiya et al.1 found
that a higher fat mass index was associated with lower
mortality rate in hemodialysis patients. Moreover, fat mass
index was positively correlated with total cholesterol in the
studied group. As the authors mention, malnutrition in
dialysis population often coexists with inflammation.
Furthermore, it is well known that ‘reverse epidemiology’
found for fat mass index is also observed for serum
cholesterol level and is also associated with inflammation in
this population.2
Recently, we tried to investigate cholesterol–inflammation
relationship in hemodialysis patients. We found that the
production of soluble components of interleukin-6 (inter-
leukin-6, soluble interleukin-6 receptor, and soluble
gp130) from activated peripheral blood mononuclear cells
isolated from hypocholesterolemic hemodialysis patients is
higher than the production of the same molecules from
monocytes isolated from hyper-cholesterolemic patients.3 In
case our data are confirmed in similar studies, it seems
that hypo-cholesterolemia – and potentially low fat mass – is
not simply associated but may also be causally related
to the production of soluble components of a crucial
proinflammatory and potentially atherogenic cytokine, as
interleukin-6, by an also crucial for atherosclerotic process
cell type, namely the circulating monocyte. Cellular choles-
terol depletion may be the link connecting hypo-cholester-
olemia and increased interleukin-6 components’
production.4
Thus, as the study of Kakiya et al. showed, ‘reverse
epidemiology’ regarding low fat mass – and potentially
hypo-cholesterolemia – is a reality that may also be causally
linked to the high inflammatory activity observed in this
population; this later hyper-reactivity may be implicated
in the evolution of processes like atherosclerosis,5 which
explain lower survival of hemodialysis patients with low fat
mass.
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